Tyme Technologies Inc. (TYME)

[mcsharkey]

Thanks Foose, appreciate it. I was ready to light up some Havanna's and pop open my last 2006 Dom Perignon bottle myself. Thinking we're at the starting line of a high-volume swings, similar to the wild rides you and Stonybrook went through back in the spring of this year.

Traders have been pretty apathetic till today. Guessing we were played well on the day trades:[/quote]

[/quote] That chart is a little deceiving in the lack of resolution. Couple of points:
  (1) We had +12435.93% of our average volume today
  (2) Darkside sales over on the DTCC was equally increased
  (3) All those trades have 17.7 Days to cover.[/quote]¯\_(?)_/¯

Dunno. We do have both our founders slowly selling down in separate 10b5-1 agreements. One of the founders was removed from his operational role, seemed like a payback where his almost weekly 20K sell off is required to be a little less than retail at that moment. Countered by the new plan established by our CEO, his sales lead the current retail winding up as the high for the day. Some kind of algorithm there for a savvy daytrader. Other issues in our Board of Directors, very popular COO left with a 1 month notice. Recent annual vote had one director barely scrape by with enough votes. TYME is close to 60% insider-owned, so someone was looking to warn him of something. Drama going on.

If the end on 2020 is our banner time, any other announcement will bring on an incredible short squeeze. Hopefully, this Proof-of-Concept RESPOnD trial gets through to an Emergency Use Authorization (EUA) stage SOON. Kind of like the waits you had with Heyward. At this stage though, we're just a month past a full year since completion of what appeared like a very successful clinical trial on Prostate Cancer "CURED". The END POINT is complete remission vs. recurrence. We've been promised the END POINT this last ½-of-year, this year, we're down to last ⅓-d now. Releasing of POSITIVE data would provide for a great short squeeze.

We've very recently been given fairly promising FDA ratings for ongoing clinical trials in both Pancreatic Cancer as well blood-borne cancers within Sacrcoma family. Pancreatic effort now eligible for government funding/grants as an ORPHAN Drug (understudied cancer). Sarcoma is continuing with some promise, no data.

Hoping we're at the bottom, you're a player, told me earlier we were like clock work between $1.20 to $1.40. Been damn boring here as noted earlier. We're not the slam-dunk I thought we'd be at this stage. But I do think a player like you can find a ride here.

GLTUA